###begin article-title 0
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA
###end article-title 0
###begin p 1
###xml 34 58 34 58 <email xmlns:xlink="http://www.w3.org/1999/xlink">Bruce.Trapnell@cchmc.org</email>
CORRESPONDENCE Bruce C. Trapnell: Bruce.Trapnell@cchmc.org
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 602 608 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 709 715 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1497 1503 1482 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 279 283 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1229 1236 <span type="species:ncbi:9606">patient</span>
###xml 1358 1366 <span type="species:ncbi:9606">children</span>
###xml 1456 1462 <span type="species:ncbi:9606">humans</span>
Primary pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by accumulation of surfactant in the lungs that is presumed to be mediated by disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling based on studies in genetically modified mice. The effects of GM-CSF are mediated by heterologous receptors composed of GM-CSF binding (GM-CSF-Ralpha) and nonbinding affinity-enhancing (GM-CSF-Rbeta) subunits. We describe PAP, failure to thrive, and increased GM-CSF levels in two sisters aged 6 and 8 yr with abnormalities of both GM-CSF-Ralpha-encoding alleles (CSF2RA). One was a 1.6-Mb deletion in the pseudoautosomal region of one maternal X chromosome encompassing CSF2RA. The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells. Transfection of cloned cDNAs faithfully reproduced the signaling defect at physiological GM-CSF concentrations. Interestingly, at high GM-CSF concentrations similar to those observed in the index patient, signaling was partially rescued, thereby providing a molecular explanation for the slow progression of disease in these children. These results establish that GM-CSF signaling is critical for surfactant homeostasis in humans and demonstrate that mutations in CSF2RA cause familial PAP.
###end p 3
###begin p 4
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 430 431 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 533 534 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 568 569 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 571 572 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 591 592 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 646 647 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 683 684 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 228 232 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 540 544 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Pulmonary surfactant homeostasis is maintained by the balanced production of surfactant by alveolar epithelium and its clearance by pulmonary alveolar macrophages (1). GM-CSF is a critical regulator of surfactant homeostasis in mice (1). GM-CSF, via heterologous cell surface receptors comprised of alpha and beta glycoprotein subunits (GM-CSF-Ralpha and GM-CSF-Rbeta, respectively), activates STAT5 and other signaling pathways (2). N-linked glycosylation of the alpha subunit is required for GM-CSF binding and receptor signaling (3). In mice, deficiency of GM-CSF (4, 5) or its receptor (6) impairs multiple functions of alveolar macrophages (7), including surfactant catabolism (8), which results in progressive surfactant accumulation.
###end p 4
###begin p 5
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 689 691 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 693 695 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 833 835 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1010 1011 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1144 1146 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1155 1157 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1170 1172 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1363 1365 1360 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 813 819 <span type="species:ncbi:9606">humans</span>
###xml 1417 1425 <span type="species:ncbi:9606">children</span>
Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by respiratory failure caused by pulmonary surfactant accumulation (9, 10), which can be grouped into distinct categories based on clinical, histopathologic, biochemical, and genetic data (1, 9-12). Primary PAP occurs when GM-CSF signaling is disrupted, for example in individuals with high levels of GM-CSF autoantibodies, which are presumed to mediate pathogenesis by neutralizing GM-CSF and reducing surfactant catabolism by alveolar macrophages (10, 13). This form, referred to as autoimmune PAP, comprises 90% of cases (13). Primary PAP has also been associated with reduced detection of GM-CSF-Rbeta on myeloid cells (14, 15), but definitive studies demonstrating heritable deficiency of either GM-CSF or its receptors as the cause of PAP in humans are lacking (16). Secondary PAP occurs as a consequence of an underlying disease presumed to impair surfactant clearance by reducing either the numbers or functions of alveolar macrophages (9). Hereditary disorders of surfactant production, for example, because of mutations in the genes encoding surfactant protein (SP)-B (17), SP-C (18), or ABCA3 (19), exhibit disordered surfactant homeostasis to varying degrees but are distinguished from PAP by their surfactant dysfunction, disruption of alveolar wall architecture, and clinical course (20). In this paper, we describe a family in which two children developed primary PAP in association with loss of GM-CSF responsiveness caused by mutations in the gene encoding GM-CSF-Ralpha.
###end p 5
###begin title 6
RESULTS AND DISCUSSION
###end title 6
###begin title 7
Clinical presentation and phenotype
###end title 7
###begin p 8
###xml 892 900 892 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 965 973 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1203 1211 1203 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1409 1411 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1413 1415 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 10 17 <span type="species:ncbi:9606">patient</span>
###xml 1049 1056 <span type="species:ncbi:9606">patient</span>
###xml 1087 1095 <span type="species:ncbi:9606">Children</span>
###xml 1380 1388 <span type="species:ncbi:9606">patients</span>
###xml 1403 1407 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The index patient presented at age six with a 2-yr history of progressive tachypnea and failure to thrive (height and weight were third percentile for age [Fig. S1 A, available at ]). Gestation, delivery, birth weight (3.66 kg, 50th percentile), and development were all normal, but weight gain slowed by 6-9 mo as did height by 2-3 yr. There was no history of cough, fever, chest pain, pneumonia or other pulmonary disease, environmental exposure, or drug use. Both parents were well-developed and healthy with no history of lung disease. Examination revealed moderate tachypnea, mild tachycardia, and inspiratory crackles but was otherwise unremarkable. Pulmonary function testing revealed severe restrictive impairment. Oxygen saturation was 88% while breathing room air and decreased while talking or walking a short distance. A diagnosis of PAP was suspected based on chest radiography (Fig. 1 A) and established by histopathologic examination of lung tissue (Fig. 1 B). A serum GM-CSF autoantibody test (21) was negative on two occasions. The patient was transferred to Cincinnati Children's Hospital and underwent whole lung lavage therapy with marked symptomatic and radiographical improvement (Fig. 1 C). MCP-1 and M-CSF levels in the lavage were increased compared with healthy controls (supplemental text, available at ), which is similar to findings in autoimmune PAP patients and GM-CSF KO mice (22, 23).
###end p 8
###begin p 9
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phenotypic characterization of patients with familial PAP.</bold>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 254 261 <span type="species:ncbi:9606">patient</span>
###xml 701 708 <span type="species:ncbi:9606">patient</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
Phenotypic characterization of patients with familial PAP. (A) Chest radiograph (top) and high-resolution computed tomogram of the chest (bottom) of the index patient at presentation. (B) Histopathologic appearance of the open lung biopsy from the index patient after staining with hematoxylin and eosin (H&E) or immunostaining for SP-A, mature SP-B, Pro-SP-C, SP-D, and ABCA3. Note the lymphocytosis in the low-power hematoxylin and eosin-stained section and the intact alveolar wall in the high-powered hematoxylin and eosin-stained section. Images were obtained at a total magnification of 50x (top) or 400x (all others). Bars: (top) 100 mum; (all others) 10 mum. (C) Chest radiograph of the index patient 4 mo after presentation immediately before (top) and 5 d after (bottom) whole lung lavage therapy. (D) Serum SP-D levels in affected siblings, parents, and a control. The mean +/- SD serum SP-D concentration in 67 healthy controls was 63.5 +/- 39 ng/ml (hatched region) and in 12 patients with autoimmune PAP was 174 +/- 83 ng/ml (not indicated). (E) High-resolution computed tomogram showing diffuse patchy ground glass opacities representing mild PAP in the affected sister.
###end p 9
###begin p 10
###xml 158 166 158 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 501 509 501 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 924 932 924 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 453 460 <span type="species:ncbi:9606">patient</span>
###xml 530 537 <span type="species:ncbi:9606">patient</span>
An inherited defect in GM-CSF receptor function was suspected based on the constellation of histopathology showing well-preserved alveolar wall architecture (Fig. 1 B), the absence of GM-CSF autoantibodies (21), and an abnormal CD11b stimulation index test (24). Therefore, all immediate family members were evaluated. Because SP is in serum in PAP and levels reflect lung disease severity (25), serum SP-D was measured and found to be increased in the patient compared with her parents and controls (Fig. 1 D). Unexpectedly, the patient's 8-yr-old sister, who was previously thought to be healthy, had increased serum SP-D. Subsequent clinical evaluation revealed that the sister had poor growth (height and weight, 10th percentile for age; Fig. S1B), a diffusion capacity for carbon dioxide of 57% that predicted, and mild patchy ground glass opacities throughout both lungs, which are consistent with a diagnosis of PAP (Fig. 1 E).
###end p 10
###begin title 11
Structure and function of the GM-CSF receptor
###end title 11
###begin p 12
###xml 117 125 110 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 311 319 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 540 548 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 840 848 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 1047 1049 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 1091 1097 1080 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1372 1380 1361 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 1512 1520 1501 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 F</xref>
###xml 1624 1632 1613 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 G</xref>
###xml 215 222 <span type="species:ncbi:9606">patient</span>
###xml 531 538 <span type="species:ncbi:9606">patient</span>
###xml 771 778 <span type="species:ncbi:9606">patient</span>
###xml 1108 1112 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1592 1599 <span type="species:ncbi:9606">patient</span>
Flow cytometry indicated that GM-CSF-Ralpha and GM-CSF-Rbeta were present on blood leukocytes in all family members (Fig. 2 A). Western blotting revealed an abnormal electrophoretic pattern for GM-CSF-Ralpha in the patient and her sister with predominantly lower molecular mass forms compared with the control (Fig. 2 B). The father was heterozygous for normal and lower molecular mass forms. Unexpectedly, the mother exhibited only a normal pattern. To evaluate cell-mediated clearance of GM-CSF, blood mononuclear cells from the patient (Fig. 2 C) and her sister (Fig. S2, available at ) were incubated with GM-CSF, and both failed to clear GM-CSF in contrast to control and parental leukocytes. The concentration of GM-CSF in lung lavage was markedly increased in the patient compared with healthy controls, in whom it was undetectable (Fig. 2 D). The in vivo concentration of pulmonary GM-CSF in the epithelial lining fluid of the lungs was estimated to be 6.9 and 27 ng/ml (right and left lungs, respectively) using the urea dilution method (26). Pulmonary GM-CSF was also increased in CSF2RB-deficient mice (Fig. S3), confirming the relationship between GM-CSF receptor dysfunction and increased pulmonary GM-CSF levels. Serum GM-CSF was increased in both affected siblings and undetectable in both parents and control, indicating that the abnormality was systemic (Fig. 2 E). GM-CSF receptor function was impaired in both affected siblings, as shown by reduced GM-CSF-stimulated phosphorylation of STAT5 (Fig. 2 F) and failure of GM-CSF to increase CD11b levels on leukocytes from the patient compared with controls (Fig. 2 G).
###end p 12
###begin p 13
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural and functional analysis of GM-CSF receptor defects.</bold>
###xml 1219 1221 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 353 360 <span type="species:ncbi:9606">patient</span>
###xml 657 664 <span type="species:ncbi:9606">patient</span>
Structural and functional analysis of GM-CSF receptor defects. (A) Flow cytometry demonstrating GM-CSF-Ralpha and GM-CSF-Rbeta on the cell surface of peripheral blood leukocytes in all family members. (B) Western blots of PBMC lysates using antibodies to detect GM-CSF-Ralpha or actin as indicated. (C) GM-CSF clearance assay. Blood leukocytes from the patient were unable to remove exogenous GM-CSF added to culture medium at time zero in contrast to leukocytes from two controls that rapidly bound and cleared GM-CSF. Error bars show the means +/- SE. (D and E) Measurement of GM-CSF concentration by ELISA. GM-CSF was readily detected in lavage from the patient but was not detected (ND) in lung lavage from nine healthy controls (D). GM-CSF was detected in the serum of affected siblings but not their parents or a control (E). (F) Blood leukocytes isolated from the indicated family members were incubated for 15 min in the absence (-) or presence (+) of 10 ng/ml GM-CSF, followed by Western blotting of cell lysates to detect total STAT5 (STAT5), phosphorylated STAT5 (pSTAT5), or actin. (G) Measurement of the GM-CSF-stimulated increase in CD11b levels on leukocytes in whole blood. The CD11b stimulation index (24) was calculated as the mean fluorescence of CD11b on leukocytes incubated with GM-CSF minus that of unstimulated cells divided by that of unstimulated cells and multiplied by 100. (H) Similar to F except that a higher GM-CSF concentration (1,000 ng/ml) was used and cell lysates were immunoprecipitated with anti-STAT5 antibody before Western blotting to detect total STAT5 (STAT5) or phosphorylated STAT5 (pSTAT5).
###end p 13
###begin p 14
###xml 395 403 391 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 H</xref>
The slower-than-expected rate of progression of PAP in both affected siblings led us to hypothesize that the GM-CSF-Ralpha abnormality may not completely abolish GM-CSF signaling. This was confirmed by incubation of primary blood mononuclear cells with a higher concentration of GM-CSF (1,000 ng/ml), which resulted in partial receptor signaling as shown by an increase in phosphorylated STAT5 (Fig. 2 H). Thus, although both GM-CSF-Ralpha and beta chains were present on leukocytes in all family members, in the two affected siblings, the GM-CSF-Ralpha chain was structurally abnormal, which severely reduced but did not completely abolish GM-CSF binding and GM-CSF-dependent signaling and cellular functions.
###end p 14
###begin title 15
Genetic analysis of the GM-CSF receptor
###end title 15
###begin p 16
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 221 229 219 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 349 350 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 352 354 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 396 402 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 402 407 400 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 416 422 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 422 424 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 435 443 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 463 469 461 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 469 471 467 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 509 517 507 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 536 542 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 789 795 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 900 906 898 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1002 1008 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 936 943 <span type="species:ncbi:9606">patient</span>
The nucleotide sequence of the CSF2RA gene in genomic DNA from both siblings revealed a single G-->A point mutation in exon 7 that encoded a nonconservative amino acid change (glycine to arginine) at position 174, G174R (Fig. 3 A). This change alters one of the 11 potential sites of N-glycosylation, which is required for GM-CSF receptor function (3, 27). The father was heterozygous for mutant CSF2RAG174R and WT (CSF2RAWT) alleles (Fig. 3 A), whereas only the CSF2RAWT sequence was detected in the mother (Fig. 3 A). The sequence of CSF2RA in leukocyte messenger RNA (mRNA) was similar to the respective DNA sequence for each family member, even when cDNA was overamplified to detect potentially underrepresented mRNA sequences (unpublished data). This absence of a normal sequence for CSF2RA exon 7 in both siblings and the absence of the point mutation in the mother suggested that one maternal CSF2RA allele may be deleted in the patient, her sister, and their mother. The nucleotide sequence of CSF2RB in leukocyte mRNA from all family members was normal (unpublished data).
###end p 16
###begin p 17
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genetic analysis of <italic>CSF2RA</italic> gene defects.</bold>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 460 466 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1968 1974 1942 1948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1974 1979 1948 1953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 2478 2484 2452 2458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 3058 3064 3032 3038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 3137 3143 3111 3117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 3184 3190 3158 3164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 3290 3296 3264 3270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 259 266 <span type="species:ncbi:9606">patient</span>
###xml 516 523 <span type="species:ncbi:9606">patient</span>
###xml 762 769 <span type="species:ncbi:9606">patient</span>
###xml 1034 1041 <span type="species:ncbi:9606">patient</span>
###xml 1132 1139 <span type="species:ncbi:9606">patient</span>
###xml 1433 1440 <span type="species:ncbi:9606">patient</span>
###xml 2162 2169 <span type="species:ncbi:9606">patient</span>
###xml 2727 2734 <span type="species:ncbi:9606">patient</span>
###xml 2875 2882 <span type="species:ncbi:9606">patient</span>
Genetic analysis of CSF2RA gene defects. (A) Nucleotide sequence of CSF2RA in genomic DNA from each family member, including nt 580-591 of the coding sequence (numbered relative to the initiation codon; from GenBank/EMBL/DDBJ under accession no. ). The index patient and her sister exhibited only a G-->A point mutation at nt 586. The father was heterozygous for this substitution and the mother exhibited only the normal sequence. (B) FISH analysis to detect CSF2RA sequences in genomic DNA from the father and the patient. The probe (CTD-3047L21), which maps to the pseudoautosomal region (Xp22.33 and Yp11.32), hybridized to both X and Y chromosomes in the father (white arrows) and to one (white arrow), but not the other (yellow arrow), X chromosome in the patient. 8-10 metaphase cells and 25 interphase cells were evaluated for each individual. Similar FISH analyses are shown for each family member in the supplemental material (available at ). Images were obtained at a total magnification of 1000x. (C) CGH analysis for the patient in the region of Xp22.33. The relative fluorescence of fluorescently labeled DNA from the patient (open circles) compared with a same-sex reference DNA (filled circles) after hybridization to various BAC clones on the SignatureSelect V2 chip representing the Xp22.33 region is shown. Reduced hybridization to several BAC clones (clones B and C) is indicated by the lower fluorescence of the patient's DNA compared with the reference DNA for these BAC clones. The telomeric breakpoint is mapped to between clones A and B and the centromeric breakpoint is mapped to between clones C and D. These data indicate an interstitial deletion of approximately1.264 Mb at Xp22.33 encompassing approximately1,610,183-2,873,864 bp. The dashed line represents a relative fluorescence of zero. (D) High-resolution SNP mapping of the Xp22 region for paternal and maternal X chromosomes. A schematic shows the locations of the point mutation (CSF2RAG174R) in the paternal X chromosome and the 1.6-Mb deletion at Xp22.33 in the maternal X chromosome and the genes encompassed. The base 2 ratio of normalized hybridization intensities for patient and reference samples (log R ratio) is shown. Similar SNP analyses for each family member are shown in the supplemental material (available at ). (E) Map showing a portion of the X chromosome summarizing the genetic analysis used to identify the small maternal X chromosomal deletion at Xp22.33 encompassing CSF2RA. The probe used for FISH analysis (hatched bar) is the same as clone B on the CGH microarray chip. The locations of selected CGH microarray probes in the region of the CSF2RA gene are shown. Those CGH probes showing balanced hybridization to patient and control DNA are shown as clear boxes (A and D), whereas those showing an unbalanced hybridization representing sequences deleted in the patient are shown in black. High-resolution SNP analysis revealed that the deletion (red bar) extended from 1,308,324 to 2,881,011 bp. Sequence analysis (A) and PCR quantification of CSF2RA exon 7 (Fig. S4, available at ) demonstrated that the deletion included CSF2RA exon 7. The chromosomal location of the CSF2RA gene (1,347,701-1,388,827 bp) is indicated. (F) Pedigree of the family deduced from sequencing and CSF2RA allelic copy number determination experiments. The index case is indicated (arrow).
###end p 17
###begin p 18
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 543 551 543 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 858 866 846 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1079 1087 1067 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1164 1170 1152 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1179 1187 1167 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 1224 1230 1212 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 534 541 <span type="species:ncbi:9606">patient</span>
###xml 849 856 <span type="species:ncbi:9606">patient</span>
PCR amplification demonstrated a reduced copy number of CSF2RA in genomic DNA from both siblings and their mother compared with the father and a healthy control (Fig. S4, available at ). In contrast, the genomic copy number of CSF2RB was similar in all family members and a control (Fig. S4). Routine cytogenetic analysis was normal in all family members (Fig. S5), ruling out a large chromosomal abnormality. Fluorescent in situ hybridization (FISH) demonstrated a deletion in the pseudoautosomal region 1 of the X chromosome in the patient (Fig. 3 B), her sister, and mother (Fig. S6) that was not present in the father (Fig. 3 B). Further evaluation using comparative genomic hybridization (CGH) demonstrated an interstitial deletion encompassing the region from approximately1,610,183 to 2,873,864 bp on one maternal-derived X chromosome in the patient (Fig. 3 C), her sister, and mother (not depicted). High-resolution single-nucleotide polymorphism (SNP) mapping further defined this small deletion as extending from 1,308,324 to 2,881,011 bp in one maternal X chromosome (Fig. 3 D) and in both siblings (Fig. S7). Importantly, this deletion encompassed the CSF2RA allele (Fig. 3 E), thereby explaining the unexpected CSF2RA DNA and mRNA sequence results.
###end p 18
###begin p 19
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 109 117 109 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
These results demonstrate the inheritance of compound heterozygous abnormalities of CSF2RA in both siblings (Fig. 3 F). The G174R mutation present on the paternal X chromosome, localized to the extracellular cytokine binding domain of GM-CSF-Ralpha, alters a potential site of glycosylation and impairs GM-CSF binding and receptor signaling. However, it is unclear if the functional impairment is caused by the change in primary amino acid sequence or loss of glycosylation.
###end p 19
###begin title 20
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 26 31 26 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
Reproduction of the CSF2RAG174R abnormality
###end title 20
###begin p 21
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 121 126 121 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 248 250 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 290 295 290 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 297 305 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 701 709 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 884 890 877 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1032 1038 1025 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1038 1040 1031 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 1045 1051 1038 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1129 1135 1122 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1135 1140 1128 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 1145 1151 1138 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1155 1161 1148 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1190 1198 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1219 1225 1212 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1240 1246 1233 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1246 1248 1239 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 1263 1269 1256 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1269 1274 1262 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 1425 1433 1418 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 1450 1456 1443 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1456 1461 1449 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 1462 1468 1455 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 1794 1802 1787 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 1567 1574 <span type="species:ncbi:9606">patient</span>
To reproduce the GM-CSF receptor signaling defect identified in this family, plasmids expressing CSF2RB and either CSF2RAG174R or CSF2RAWT were cotransfected into 293 cells. Western blotting showed receptor proteins of the expected size from CSF2RAWT and smaller molecular forms from CSF2RAG174R (Fig. 4 A), which is similar to results for primary leukocytes (Fig. 2 B). Treatment of transduced cell lysates with Peptide: N-Glycosidase F, an amidase that cleaves between the innermost GlcNAc and asparagine residues of high mannose oligosaccharides (3), resulted in a similar electrophoretic pattern for normal and G174R GM-CSF-Ralpha. This confirmed the G174R mutation alters N-linked glycosylation (Fig. 4 A) by disrupting a functional N-linked glycosylation site and that glycosylation is responsible for the smaller molecular forms from this allele. GM-CSF-Rbeta was expressed in CSF2RB-transfected cells but was undetectable in nontransfected cells (unpublished data). GM-CSF binding studies demonstrated that cells expressing CSF2RAWT and CSF2RB rapidly bound GM-CSF and removed it from the media, whereas cells expressing CSF2RAG174R and CSF2RB or CSF2RB alone did not clear GM-CSF (Fig. 4 B). Cotransfection of CSF2RB together with CSF2RAWT, but not with CSF2RAG174R, resulted in expression of functional GM-CSF receptors as demonstrated by GM-CSF-dependent phosphorylation of STAT5 only with the former combination (Fig. 4 C). Incubation of CSF2RAG174R/CSF2RB-transduced cells with higher concentrations of GM-CSF in the range of those observed in the index patient gave results similar to those obtained with primary leukocytes and clearly demonstrated a modest dose-dependent increase in STAT5 phosphorylation, which is consistent with a partial rescue of the signaling abnormality (Fig. 4 D).
###end p 21
###begin p 22
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 26 31 26 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reproduction of the <italic>CSF2RA</italic><sup>G174R</sup> gene defect.</bold>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 189 191 189 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 206 211 206 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 556 562 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 562 564 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 565 571 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 603 609 599 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 609 614 605 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
###xml 615 621 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 623 629 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
Reproduction of the CSF2RAG174R gene defect. (A) Western blots of nontransfected 293 cell lysates (control) or lysates of cells transfected with plasmids expressing CSF2RB and either CSF2RAWT (WT) or CSF2RAG174R (G174R), followed by incubation with (+) or without (-) Peptide: N-Glycosidase F (PNGase F) and detection with antibodies against GM-CSF-Ralpha or actin. (B) Evaluation of cell-mediated binding and removal of exogenous GM-CSF from the culture media. Asterisks indicate significant differences in levels of GM-CSF in media from cells expressing CSF2RAWT/CSF2RB compared with cells expressing CSF2RAG174R/CSF2RB, CSF2RB alone or media without cells. Error bars show the means +/- SE. (C) Evaluation of GM-CSF-stimulated phosphorylation of STAT5 in 293 cells transfected as described in A and incubated for 15 min in the absence (-) or presence (+) of 10 ng/ml GM-CSF. Lysates were evaluated by Western blotting (WB) to detect total STAT5 (STAT5) or were immunoprecipitated with anti-STAT5 antibody and then evaluated by Western blotting (IP + WB) to detect total STAT5 or phosphorylated STAT5 (pSTAT5). (D) Similar to C, except that increased concentrations of GM-CSF were used for evaluate GM-CSF receptor function.
###end p 22
###begin title 23
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 32 37 32 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G174R</sup>
Clinical relevance of the CSF2RAG174R mutation
###end title 23
###begin p 24
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 478 479 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 480 481 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 638 639 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 641 643 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 54 60 <span type="species:ncbi:9606">humans</span>
###xml 309 315 <span type="species:ncbi:9606">humans</span>
###xml 472 476 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 630 636 <span type="species:ncbi:9606">humans</span>
Our findings demonstrate that familial primary PAP in humans is caused by compound heterozygous abnormalities of CSF2RA, including loss of heterozygosity and a function-altering point mutation that severely reduces GM-CSF receptor signaling. These are the first results to demonstrate familial primary PAP in humans and that GM-CSF-Ralpha is critical for surfactant homeostasis. They extend previous findings that PAP is caused by the absence of GM-CSF or GM-CSF-Rbeta in mice (4-6) or is specifically associated with the presence of neutralizing GM-CSF autoantibodies or a reduction in alveolar macrophage numbers or function in humans (9, 10). The allelic frequency of these mutations has not been determined but may be rare given that autoantibodies against GM-CSF account for most individuals with PAP.
###end p 24
###begin p 25
###xml 263 267 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SHOX</italic>
###xml 269 291 269 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">short stature homeobox</italic>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 148 156 <span type="species:ncbi:9606">children</span>
###xml 533 540 <span type="species:ncbi:9606">patient</span>
Both affected siblings had impaired pulmonary function and failure to thrive, supporting the conclusion that prolonged respiratory insufficiency in children retards growth. Important to this conclusion is the observation that Xp22.33 deletion did not include the SHOX (short stature homeobox) gene, the deletion of which impairs growth (28). Further, heterozygous loss of CSF2RA in the mother did not impair growth. Early results suggest that whole lung lavage therapy was followed by an increase in growth acceleration in the index patient.
###end p 25
###begin p 26
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 908 909 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 911 912 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
###xml 425 432 <span type="species:ncbi:9606">patient</span>
###xml 935 941 <span type="species:ncbi:9606">humans</span>
This study highlights the usefulness of several novel biomarkers in the diagnostic evaluation of PAP. The combination of a negative GM-CSF autoantibody test (29) and an abnormal CD11b stimulation index (24) predicted the GM-CSF receptor dysfunction, which was confirmed by the lack of GM-CSF binding and defective GM-CSF receptor signaling. GM-CSF levels were increased in lung lavage from the patient and, in serum from the patient and her sister, compared with family members and healthy controls. Because primary PAP is presumed to be caused by a defect in GM-CSF regulation of alveolar macrophage surfactant catabolism (9, 10), an elevated serum GM-CSF level may be useful as a biomarker to distinguish primary PAP caused by GM-CSF autoantibodies (90% of all cases of PAP) (9, 10, 13, 30) from PAP caused by GM-CSF receptor dysfunction (this study; references 14-16) and PAP caused by GM-CSF deficiency (4, 5) (not yet reported in humans). Finally, an increased serum SP-D level predicted the occurrence of PAP in the sister, which was confirmed by subsequent clinical and radiographical evaluation.
###end p 26
###begin p 27
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 1129 1135 1125 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 972 979 <span type="species:ncbi:9606">patient</span>
The slow progression and differences in severity of the lung disease between affected siblings with the same CSF2RA mutations and GM-CSF-Ralpha dysfunction indicates that penetrance is important in familial PAP because of GM-CSF receptor defects. The increased levels of GM-CSF likely reflect impaired clearance but are also consistent with interruption of a negative-feedback regulatory loop. Results strongly suggest that the high levels of pulmonary GM-CSF present in epithelial lining fluid result in a reduced but not abrogated receptor signaling and provide a molecular explanation the slow progression of PAP in both affected siblings. It is currently unclear if the level of increased pulmonary GM-CSF correlates with disease severity. They also suggest that aerosolized delivery of GM-CSF to the lungs may be therapeutic because this approach could theoretically achieve pulmonary GM-CSF levels several thousand-fold higher than endogenous levels measured in the patient and 20-fold higher than levels that appeared to completely restore GM-CSF receptor signaling in the transfection experiments. BM transplantation and CSF2RA gene transfer represent other potentially therapeutic approaches.
###end p 27
###begin p 28
The identification of mild PAP in the older sister provides a unique and important opportunity to observe PAP at a very early stage of disease development. Finally, this case exemplifies the utility of a collaborative approach to the diagnosis and treatment of individuals with very rare diseases involving geographically disparate clinical centers and the benefit derived from integrating basic science, clinical medicine, and translational research.
###end p 28
###begin title 29
MATERIALS AND METHODS
###end title 29
###begin title 30
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants.
###end title 30
###begin p 31
###xml 49 57 <span type="species:ncbi:9606">Children</span>
###xml 112 124 <span type="species:ncbi:9606">participants</span>
###xml 218 230 <span type="species:ncbi:9606">participants</span>
The institutional review board of the Cincinnati Children's Hospital Medical Center approved the study, and all participants gave written informed consent or assent. Detailed case histories and laboratory data for the participants are included in the supplemental text (available at ).
###end p 31
###begin title 32
GM-CSF receptor structure and function.
###end title 32
###begin p 33
###xml 164 165 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 363 364 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 790 792 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 992 994 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1165 1167 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 644 650 <span type="species:ncbi:9913">bovine</span>
###xml 661 666 <span type="species:ncbi:9606">human</span>
###xml 894 899 <span type="species:ncbi:9606">human</span>
###xml 1007 1012 <span type="species:ncbi:9606">human</span>
GM-CSF receptors were evaluated by flow cytometry using antibodies recognizing GM-CSF-Ralpha (BD) or beta (Santa Cruz Biotechnology, Inc.) and by Western blotting (7) with chain-specific antibodies (Santa Cruz Biotechnology, Inc.). The effects of glycosylation on GM-CSF-Ralpha were evaluated by incubating cell lysates with PNGase F (New England Biolabs, Inc.) (3). Actin was measured as a loading control using anti-actin antibodies (Santa Cruz Biotechnology, Inc.). To evaluate receptor-mediated clearance of GM-CSF, Ficoll-purified blood leukocytes or 293 cells (American Type Culture Collection) were cultured in DMEM containing 10% fetal bovine serum and human GM-CSF (Leukine; Bayer) at 1 ng/ml. At subsequent times, GM-CSF was measured in the culture medium by ELISA (R&D Systems) (24). To evaluate GM-CSF receptor signaling, heparinized blood was incubated with or without 10 ng/ml of human GM-CSF Leukine for 15 min. After lysing RBC, leukocytes were evaluated by Western blotting (24) using anti-human STAT5 (Santa Cruz Biotechnology, Inc.) and anti-phospho-STAT5 (Millipore) antibodies. The CD11b stimulation index was measured as previously described (24).
###end p 33
###begin title 34
ELISA.
###end title 34
###begin p 35
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
SP-D, GM-CSF, MCP-1 (monocyte chemotactic protein-1), M-CSF, and urea were measured using commercial ELISA kits (BioVendor, R&D Systems, BD, R&D Systems, and BioAssay Systems, respectively) (24). The concentration of cytokines in epithelial lining fluid of the lungs was estimated by multiplying the concentration in lavage fluid by the ratio of urea concentrations in serum and lavage fluid (26).
###end p 35
###begin title 36
Genetic analysis.
###end title 36
###begin p 37
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 517 523 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RB</italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
Genomic DNA or total mRNA was purified from blood leukocytes with commercially available kits (QIAGEN). The PCR was used to generate products spanning exons and flanking intronic sequences (genomic DNA) or the coding sequences and 5' and 3' flanking untranslated sequences (mRNA) of the CSF2RA and CSF2RB genes, which were then analyzed by direct sequencing. The resulting sequences were compared with published sequences (from GenBank/EMBL/DDBJ under accession nos.  and , respectively). The relative copy number of CSF2RA and CSF2RB genes among family members and a healthy control was measured by amplification of genomic DNA using PCR with gene-specific oligonucleotides followed by analysis of products by electrophoresis on 2% agarose gels. Experimental methods for measuring gene copy number, evaluating the genes encoding SP-B, SP-C, and ABCA3 (19, 31) for function-altering mutations, cytogenetic analysis, CGH analysis, FISH, and high-resolution SNP array analysis (32) are described in the supplemental Materials and methods (available at ).
###end p 37
###begin title 38
Reproduction of the GM-CSF receptor defect.
###end title 38
###begin p 39
The methods used to clone and express mRNA transcripts encoding GM-CSF-Ralpha and beta chains in cultured cells and evaluate protein glycosylation are described in the supplemental Materials and methods.
###end p 39
###begin title 40
Statistical analysis.
###end title 40
###begin p 41
###xml 93 94 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Numeric data are presented as means +/- SE. Statistical comparisons were made with Student's t test for two-group comparisons and with one-way analysis of variance with posthoc analysis according to the Holm-Sidak method for multiple-group comparisons. P-values of <0.05 were considered to indicate statistical significance.
###end p 41
###begin title 42
Online supplemental material.
###end title 42
###begin p 43
###xml 276 282 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Csf2rb</italic>
###xml 321 327 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 496 502 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2RA</italic>
###xml 53 60 <span type="species:ncbi:9606">patient</span>
###xml 287 291 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Fig. S1 shows normalized growth curves for the index patient and her sister. Fig. S2 shows GM-CSF binding and clearance by blood leukocytes from affected and unaffected family members and control. Fig. S3 shows increased pulmonary GM-CSF levels in GM-CSF receptor beta chain (Csf2rb) KO mice. Fig. S4 shows evaluation of CSF2RA and CSF2FB gene copy number by PCR amplification. Fig. S5 shows karyotypes of high-resolution GTG-banded chromosomes. Fig. S6 shows evaluation of heterozygosity at the CSF2RA locus by FISH. Fig. S7 shows high-resolution SNP analysis. The supplemental text contains additional details regarding the case histories and clinical laboratory and other data cited throughout the text. Online supplemental material is available at .
###end p 43
###begin title 44
Supplementary Material
###end title 44
###begin title 45
[Supplemental Material Index]
###end title 45
###begin p 46
###xml 77 85 <span type="species:ncbi:9606">Children</span>
###xml 477 485 <span type="species:ncbi:9606">Children</span>
We thank Diana Koch, Diane Black, Paula Blair, and Ralph Stanley (Cincinnati Children's Hospital Medical Center) for excellent technical assistance, Dr. Denis McGraw (University of Cincinnati Medical Center) for performing bronchoalveolar lavage in healthy controls, Dr. Frank McCormack (University of Cincinnati College of Medicine) for helpful discussions, and Lauren Vannoy (Wake Forest University School of Medicine and the Translational Research Trials Office, Cincinnati Children's Hospital Medical) for clinical research coordination.
###end p 46
###begin p 47
###xml 321 329 <span type="species:ncbi:9606">Children</span>
This work was supported in part by the grants from the National Center For Research Resources (RR019498 to B.C. Trapnell to support the Rare Lung Diseases Consortium) and the National Heart, Lung, and Blood Institute (HL085453 to B.C. Trapnell and HL085610 to J.A. Whitsett), and the Division of Pulmonary Biology at the Children's Hospital Medical Center.
###end p 47
###begin p 48
The authors have no conflicting financial interests.
###end p 48

